Vandetanib
- Generic Name
- Vandetanib
- Brand Names
- Caprelsa
- Drug Type
- Small Molecule
- Chemical Formula
- C22H24BrFN4O2
- CAS Number
- 443913-73-3
- Unique Ingredient Identifier
- YO460OQ37K
- Background
Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types.
On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.
- Indication
Vandetanib is currently approved as an alternative to local therapies for both unresectable and disseminated disease. Because Vandetanib can prolong the Q-T interval, it is contraindicated for use in patients with serious cardiac complications such as congenital long QT syndrome and uncompensated heart failure.
- Associated Conditions
- Metastatic Thyroid Gland Medullary Carcinoma, Locally advanced Medullary thyroid cancer
- Associated Therapies
- -
Vandetanib to Treat Advanced Kidney Cancer
- First Posted Date
- 2011-06-14
- Last Posted Date
- 2015-10-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 3
- Registration Number
- NCT01372813
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment
- Conditions
- Interventions
- First Posted Date
- 2011-02-17
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 205
- Registration Number
- NCT01298323
- Locations
- 🇦🇺
Investigational Site Number : 301, St Leonards, New South Wales, Australia
🇦🇹Investigational Site Number : 401, Wien, Austria
🇧🇪Investigational Site Number : 501, Anderlecht, Belgium
Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer
- First Posted Date
- 2010-08-31
- Last Posted Date
- 2019-05-16
- Lead Sponsor
- Cardiff University
- Target Recruit Count
- 82
- Registration Number
- NCT01191892
- Locations
- 🇬🇧
Beatson West of Scotland Cancer Centre, Glasgow, Scotland, United Kingdom
🇬🇧Royal Bournemouth General Hospital, Bournemouth, United Kingdom
🇬🇧Royal Surrey County Hospital, Surrey, United Kingdom
A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery
- First Posted Date
- 2010-08-17
- Last Posted Date
- 2021-01-22
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 9
- Registration Number
- NCT01183559
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors
- First Posted Date
- 2009-07-13
- Last Posted Date
- 2017-04-24
- Lead Sponsor
- SWOG Cancer Research Network
- Registration Number
- NCT00937417
A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)
- First Posted Date
- 2009-06-18
- Last Posted Date
- 2018-11-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 22
- Registration Number
- NCT00923247
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC
- Conditions
- Interventions
- First Posted Date
- 2009-04-13
- Last Posted Date
- 2018-09-18
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 149
- Registration Number
- NCT00880334
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-04-01
- Last Posted Date
- 2016-12-19
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 129
- Registration Number
- NCT00872989
- Locations
- 🇺🇸
Sletten Cancer Institute at Benefis Healthcare, Great Falls, Montana, United States
🇺🇸Montana Cancer Specialists at Montana Cancer Center, Missoula, Montana, United States
🇺🇸Montana Cancer Center at St. Patrick Hospital and Health Sciences Center, Missoula, Montana, United States
Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD)
- First Posted Date
- 2009-03-17
- Last Posted Date
- 2016-10-10
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 15
- Registration Number
- NCT00862836
- Locations
- 🇩🇪
Research Site, Berlin, Germany
Dose Escalation Study of Vandetanib With Hypofractionated Stereotactic Radiotherapy in Recurrent Malignant Gliomas
- Conditions
- Interventions
- First Posted Date
- 2009-01-15
- Last Posted Date
- 2013-06-26
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 13
- Registration Number
- NCT00822887
- Locations
- 🇺🇸
University of Colorado Health Science Center, Aurora, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.